Co-Founder & CTO Mario Schlosser Transitions to Advisor Role with Reduced Compensation
OSCR has more than doubled off its 52-week low of $10.69.
Summary
Oscar Health's co-founder and CTO, Mario Schlosser, is moving to an advisory role, stepping back from day-to-day executive duties with a reduced compensation package.
Key Events · Executive and Board Changes · OSCR
-
Executive Role Transition
Mario Schlosser, a co-founder and the President of Technology and Chief Technology Officer, is transitioning to Co-Founder & Advisor to the CEO, effective June 1, 2026.
-
Continued Board Membership
Mr. Schlosser will continue to serve on the Company's Board of Directors.
-
Compensation Changes
His annual base salary will be $370,000, and he will no longer be eligible for annual bonuses or new long-term incentive/equity awards. He will also not receive cash severance or subsidized healthcare upon termination.
-
Focus on Innovation
In his new advisory role, Mr. Schlosser will focus on accelerating the company's artificial intelligence and digital health agenda.
Analysis · OSCR · Finance
Mario Schlosser, a co-founder and the President of Technology and CTO, is transitioning to an advisory role. While he will continue to focus on AI and digital health and remain on the board, his operational responsibilities are decreasing, reflected in a lower base salary and ineligibility for future bonuses or equity awards. This marks a significant shift in leadership for a key executive.
At the time of this filing, OSCR was trading at $22.85 on NYSE in the Finance sector, with a market capitalization of approximately $6.1B. The 52-week trading range was $10.69 to $25.58. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.